Rafael Holdings, Inc. (New York Stock Exchange:RFL)
| Market Cap | 80.92M+15.8% |
| Revenue (ttm) | 980.00K+33.9% |
| Net Income | -32.55M-42.2% |
| EPS | -0.68+27.4% |
| Shares Out | 51.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Dec 18, 2009 |
| Volume | 57,309 |
| Open | 1.53 |
| Previous Close | 1.48 |
| Day's Range | 1.50 - 1.59 |
| 52-Week Range | 1.12 - 3.96 |
| Beta | 0.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About RFL
Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
$RFL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RFL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RFL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RFL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
RFL Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Balance as of July 31, 2025 | $19.94M | 50.00% |
| Balance as of April 30, 2026 | $19.94M | 50.00% |
As of: Q2 2026 (Apr 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New RFL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RFL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RFL
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $2.51M |
| VXFVanguard Extended Market ETF | $1.22M |
| IWCiShares Micro-Cap ETF | $154.67K |
| DFMCU.S. Micro Cap Portfolio ETF | $137.21K |
| DFASDimensional - US Small Cap ETF | $66.26K |
| DFACDimensional - US Core Equity 2 ETF | $53.93K |
Estimated from each fund’s disclosed top holdings × AUM
RFL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RFL’s recent data — informational, not investment advice